Journey Medical regains Nasdaq equity compliance after $19M Maruho license

Journey Medical Corp

Previously disclosed Nasdaq Staff notified Company of non-compliance with $2.5M stockholders' equity requirement on August 15, 2023.
On August 31, 2023, entered exclusive license agreement with Maruho for Qbrexza; Maruho paid $19M.
Company now believes it satisfies Stockholders' Equity Requirement and awaits formal Nasdaq determination.
Company had deadline of September 29, 2023 to submit compliance plan if needed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.